NCT06693375View on ClinicalTrials.gov

To Evaluate Dose and Safety of NanoEcho Particle-1 Using NanoEcho Imaging Device Examinations of Rectal Lymph Nodes in Healthy Volunteers and Rectal Cancer Patients.

PHASE2RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 29, 2024

Primary Completion Date

May 31, 2026

Study Completion Date

June 30, 2026

Conditions
Healthy VolunteersRectal Cancer Patients
Interventions
DRUG

Iron oxide nanoparticles

Submucosal injection of nanoparticles in rectum, 28 mg Fe (7 mg Fe/mL)

DEVICE

Rectal Magnetomotoric ultrasound (MMUS)

MMUS examination of lymphnodes in rectum

DRUG

Iron oxide nanoparticles

Submucosal injection in rectum 56 mg Fe (3,5 mg Fe/mL)

DRUG

Iron oxide nanoparticles

Submucosal injection in rectum : 56 mg Fe (14 mg Fe/mL)

DRUG

Iron oxide nanoparticles

Submucosal injection in rectum 112 mg Fe (14 mg Fe/mL)

Trial Locations (1)

75237

RECRUITING

Clinical Trial Consultants, Uppsala

Sponsors

Lead Sponsor

NanoEcho AB
All Listed Sponsors
lead

NanoEcho AB

INDUSTRY

NCT06693375 - To Evaluate Dose and Safety of NanoEcho Particle-1 Using NanoEcho Imaging Device Examinations of Rectal Lymph Nodes in Healthy Volunteers and Rectal Cancer Patients. | Biotech Hunter | Biotech Hunter